Nuvalent (NUVL) Share-based Compensation (2020 - 2026)
Nuvalent's (NUVL) quarterly Share-based Compensation came in at $226.2 million in Q1 2026, up 28245.86% YoY from N/an in Q1 2025, and up 940.77% on a QoQ basis from $21.7 million in Q4 2025.
Analysis
Nuvalent (NUVL) Share-based Compensation (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Share-based Compensation data on file, last reported at $226.2 million in Q1 2026.
- Quarterly Share-based Compensation rose 28245.86% year-over-year to $226.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $226.2 million (up 1832.14% YoY) and the FY2025 annual result came in at $170.4 million, up 17.92% from the prior year.
- Share-based Compensation rose to $226.2 million in Q1 2026, from $21.7 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $226.2 million in Q1 2026 to a low of -$44.4 million in Q4 2024.
- A 5-year average of $19.4 million and a median of $6.9 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation tumbled 693.34% — and 2026, when it surged 28245.86%.
- Tracing NUVL's Share-based Compensation over 5 years: stood at $3.0 million in 2022, then surged by 148.26% to $7.5 million in 2023, then plunged by 693.34% to -$44.4 million in 2024, then surged by 148.91% to $21.7 million in 2025, then surged by 940.77% to $226.2 million in 2026.
- The last three Share-based Compensation figures came in at $226.2 million (Q1 2026), $21.7 million (Q4 2025), and $22.3 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | 28.88 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 28.88 Mn |
| Dec 31, 2025 | 21.73 Mn |
| Sep 30, 2025 | 22.31 Mn |
| Jun 30, 2025 | 22.07 Mn |
| Mar 31, 2025 | 20.38 Mn |
| Dec 31, 2024 | 16.14 Mn |
| Sep 30, 2024 | 15.46 Mn |
| Jun 30, 2024 | 15.13 Mn |
| Mar 31, 2024 | 13.86 Mn |
| Dec 31, 2023 | 7.49 Mn |
| Sep 30, 2023 | 6.85 Mn |
| Jun 30, 2023 | 6.15 Mn |
| Mar 31, 2023 | 6.36 Mn |
| Dec 31, 2022 | 3.02 Mn |
| Sep 30, 2022 | 5.82 Mn |
| Jun 30, 2022 | 2.45 Mn |
| Mar 31, 2022 | 2.21 Mn |
| Dec 31, 2021 | 717,000.00 |
| Sep 30, 2021 | 1.37 Mn |
| Jun 30, 2021 | 2.11 Mn |